Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients

Primary Objective of the trial is to evaluate the efficacy and safety of Isa-VRd-based regimen in transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) patients receiving treatment in real-world clinical practice in China. And Secondary Objectives is， To assess the MRD negativity rate in Chinese TI-NDMM patients treated with Isa-VRd To assess the safety and tolerability of Isa-VRd in Chinese TI-NDMM patients Participants will: Receive Isatuximab 10 mg/kg iv * Cycle 1: Every weeks on Days 1, 8, 15, and 22 * Cycles 2-8: Every 2 weeks on Days 1 and 15 Receive Bortezomib subcutaneous injection 1.3 mg/m² * Cycles 1-8: Days 1, 8, and 15 of each cycle Receive Lenalidomide oral 25 mg/day * Cycles 1-8: Days 1-21 at 25 mg/day (10 mg/day for patients with creatinine clearance \[CrCl\] ≥30 and \

Inclusion Criteria: * Age ≥18 years * Newly diagnosed transplant-ineligible multiple myeloma patients as assessed by investigator, specifically referring to CSCO guidelines * Must meet corresponding laboratory test results (refer to restrictions in package inserts of combination drugs): * Absolute neutrophil count (ANC) ≥1.0×10⁹/L * Platelet count ≥50×10⁹/L * Calculated creatinine clearance ≥30 mL/min (using Cockcroft-Gault formula) * Total bilirubin ≤3× upper limit of normal (ULN) * TI-NDMM patients intended for Isa-VRd regimen treatment as determined by investigator judgment, independent of study objectives Signed informed consent form (by patient or their legal representative) Exclusion Criteria: * Patients currently participating in other interventional clinical studies * Patients with known severe hypersensitivity reactions to Isatuximab or any other excipients * Severe bacteremia at the time of administration * Currently uncontrolled cardiovascular disease, including: * Uncontrolled hypertension * Uncontrolled arrhythmia * Uncontrollable congestive heart failure * Unstable angina * Patients with peripheral neuropathy ≥Grade 2 * Active infectious disease, known human immunodeficiency virus (HIV) positivity, active hepatitis B or hepatitis C * Patients who are currently pregnant * Patients who, at the physician's discretion, are unable to tolerate any drug in the combination regimen